We are live on ! Find out more
TRIL

Trillium Therapeutics Inc.
TRIL

Delisted

TRIL was delisted on the 16th of November, 2021.

34 hedge funds and large institutions have $69.9M invested in Trillium Therapeutics Inc. in 2015 Q2 according to their latest regulatory filings, with 21 funds opening new positions, 5 increasing their positions, 6 reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

2,000% more first-time investments, than exits

New positions opened: 21 | Existing positions closed: 1

267% more capital invested

Capital invested by funds: $19M → $69.9M (+$50.9M)

143% more funds holding

Funds holding: 1434 (+20)

17% less repeat investments, than reductions

Existing positions increased: 5 | Existing positions reduced: 6

Holders
34
Holders Change
+20
Holders Change %
+142.86%
% of All Funds
0.92%
Holding in Top 10
1
Holding in Top 10 Change
+1
Holding in Top 10 Change %
% of All Funds
0.03%
New
21
Increased
5
Reduced
6
Closed
1
Calls
Puts
Net Calls
Net Calls Change

TRIL Hedge Fund Activity: Q2 2015 in Review

34 of the 3,712 institutional investors tracked by Wall St. Rank reported a position in Trillium Therapeutics Inc. (TRIL) for Q2 2015, worth a combined $69.9M — up 267% from $19M a quarter earlier.

Buyers outnumbered sellers: 21 funds opened new TRIL positions and 1 closed out — a net gain of 20 holders — while 5 added to existing stakes and 6 trimmed.

The largest buyer was Private Capital Advisors, adding an estimated $9.59M. The largest seller was Avoro Capital Advisors, cutting an estimated $1.51M.

  • 34 institutional investors held Trillium Therapeutics Inc. (TRIL) as of Q2 2015, up from 14 in Q1 2015.
  • Funds reported $69.9M of Trillium Therapeutics Inc. stock for Q2 2015, up 267% quarter-over-quarter.
  • 21 funds opened new Trillium Therapeutics Inc. positions in Q2 2015 and 1 closed out, a net change of +20 holders.
  • The largest Trillium Therapeutics Inc. buyer in Q2 2015 was Private Capital Advisors, an estimated $9.59M added.
  • The largest Trillium Therapeutics Inc. seller in Q2 2015 was Avoro Capital Advisors, an estimated $1.51M sold.

Based on aggregated 13F filings for Q2 2015.